A Contiguous, Sequential Phase I/II Imaging Study of 18F-fluoro-3'-L-fluorothymidine (18F-FLT)in Patients With Known or Suspected Carcinoma of the Lung, Breast, Renal Cell, Pancreas, or Brain, and With Gastrointestinal Malignancies, Neuroendocrine Tumours or Lymphoma
The Radiotracer 18F-FLT can non-invasively assess excessive cell growth in PET scan images.
Tumour growth rate is a useful indicator of tumour aggression and response to treatment.
Imaging and measuring the cell growth with 18F-FLT may be useful in monitoring response to
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society